CD44 expression in benign and malignant colorectal polyps

Diseases of the Colon and Rectum

Volumn 42, Issue 1, 1999, Pages 50-55

  Neumayer, Renate ^a   Rosen, Harald R ^a   Reiner, Angelika ^a   Sebesta, Christian ^a   Schmid, Alfons ^a   Tüchler, Heinz ^a   Schiessel, Rudolf ^a  

^a DANUBE HOSPITAL   (Austria)

Author keywords

Carcinoma in adenoma; CD44; Colorectal adenoma; Dysplasia

Indexed keywords

HERMES ANTIGEN; ISOPROTEIN; MONOCLONAL ANTIBODY;

ADENOMATOUS POLYP; ANTIGEN EXPRESSION; BENIGN TUMOR; CANCER GRADING; COLON POLYP; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; RECTUM POLYP;

ADENOMA; ANIMALS; ANTIGENS, CD44; CARCINOMA; COLONIC POLYPS; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0032944722     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02235182     Document Type: Conference Paper

References (32)

1. Alho AM, Underbill CB. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells. J Cell Biol 1989; 108:1557-65.
2. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.
3. Gunthert U. CD44 in malignant disorders. Curr Top Microbiol Immunol 1996;213:271-85.
4. Herrlich P, Zöller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993;14:395-9.
5. Koopman G, Heider KH, Horst E, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993; 177: 897-904.
6. Haynes BF, Telen MJ, Hale LP, Denning SM. CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 1989;10:423-8.
7. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56:1057-62.
8. Arch R, Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-5.
9. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991;10:343-8.
10. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
11. Hofmann M, Rudy W, Zöller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-7.
12. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993;177:443-55.
13. Heider KH, Hofmann M, Hors E, et al. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-33.
14. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61.-759-67.
15. Ilyas M, Tomlinson IP. Genetic pathways in colorectal cancer. Histopathology 1996;28:389-99.
16. Herrlich P, Pals S, Ponta H. CD44 in colon cancer. Eur J Cancer 1995;31A:1110-2.
17. Higashikawa K, Yokozaki H, Ue T, et al. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 1996;66: 11-7.
18. Imazeki F, Yokosuka O, Yamaguchi T, Ohto M, Isono K, Omata M. Expression of variant CD44-messenger RNA in colorectal adenocarcinomas and adenomatous polyps in humans. Gastroenterology 1996;110:362-8.
19. Wielenga VJ, Heider KH, Offerhaus JA, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53: 4754-6.
20. Jass JR, Sobin LH. Histological typing of intestinal tumors. 2nd ed. Berlin: Springer Verlag, 1989:29-32.
21. Sobin LH, Wittekind C (UICC), eds. TNM Classification of malignant tumors. 5th ed. Toronto: Wiley-Liss, 1997: 67-69.
22. Mulder JW, Kruyt PM, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
23. Mulder JW, Wielenga VJ, Polak MM, et al. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. Gut 1995;36:76-80.
24. Gotley DC, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM. Alternatively spliced variants of the cell adhesion molecule CD44 and tumor progression in colorectal cancer. Br J Cancer 1996;74:342-51.
25. Kallakury BV, Yang F, Figge J, et al. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer 1996;78: 1461-9.
26. Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996;149:873-82.
27. Russell JB, Chu DZ, Russel MP, Chan CH, Thompson C, Schaefer RF. When is polypectomy sufficient treatment for colorectal cancer in a polyp? Am J Surg 1990;160: 665-8.
28. Kyzer S, Begin LR, Gordon PH, Mitmaker B. The care of patients with colorectal polyps that contain invasive adenocarcinoma. Cancer 1992;70:2044-50.
29. Volk EE, Goldblum JR, Petras RE, Carey WD, Fazio VW. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology 1995;109:1801-7.
30. Whitlow C, Gathright JB Jr, Hebert SJ, et al. Long-term survival after treatment of malignant colonic polyps. Dis Colon Rectum 1997;40:929-34.
31. Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: Implications for lesions removed by endoscopic polypectomy. Gastroenterology 1985;89:328-36.
32. Geraghty JM, Williams CB, Talbot IC. Malignant colorectal polyps: venous invasion and successful treatment by endoscopic polypectomy. Gut 1991;32:774-8.